Purpose
|
LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
|
Characteristics
|
Target: RAAS inhibitor, ACE inhibitor Receptor: RAAS
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
97?% +
|
Formula
|
C24H29N5O3.C24H29NO5.5/2H2O.3Na
|
Solubility
|
30 mM in DMSO and 100mM in water.
|